CM Management LLC Has $2.24 Million Stake in Organon & Co. (NYSE:OGN)

CM Management LLC boosted its stake in Organon & Co. (NYSE:OGN - Free Report) by 50.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 150,000 shares of the company's stock after purchasing an additional 50,000 shares during the quarter. Organon & Co. comprises 1.9% of CM Management LLC's investment portfolio, making the stock its 20th biggest position. CM Management LLC owned 0.06% of Organon & Co. worth $2,238,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Pacer Advisors Inc. lifted its stake in Organon & Co. by 94,482.1% during the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company's stock worth $166,391,000 after purchasing an additional 11,140,388 shares during the last quarter. Weiss Asset Management LP bought a new stake in shares of Organon & Co. during the 3rd quarter worth $32,966,000. Jacobs Levy Equity Management Inc. boosted its stake in Organon & Co. by 303.8% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,242,135 shares of the company's stock valued at $23,762,000 after buying an additional 934,505 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Organon & Co. by 35.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 3,323,051 shares of the company's stock valued at $63,570,000 after acquiring an additional 875,128 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in Organon & Co. by 191.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 760,807 shares of the company's stock worth $11,382,000 after acquiring an additional 499,616 shares in the last quarter. Institutional investors own 77.43% of the company's stock.

Remove Ads

Organon & Co. Trading Down 3.7 %

OGN traded down $0.58 during trading on Wednesday, reaching $15.03. 3,544,567 shares of the company's stock were exchanged, compared to its average volume of 2,337,523. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. Organon & Co. has a one year low of $13.87 and a one year high of $23.10. The firm has a fifty day moving average price of $15.46 and a two-hundred day moving average price of $16.80. The stock has a market capitalization of $3.88 billion, a PE ratio of 4.51, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. As a group, equities research analysts forecast that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 13th. Investors of record on Monday, February 24th will be issued a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 7.45%. The ex-dividend date of this dividend is Monday, February 24th. Organon & Co.'s payout ratio is presently 33.63%.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on OGN shares. Morgan Stanley reduced their price target on shares of Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a research note on Friday, February 14th. Barclays decreased their target price on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Finally, TD Cowen upgraded Organon & Co. to a "hold" rating in a research note on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $20.80.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.